New insights into the management of severe sepsis and septic shock

Drotrecogin alfa (activated protein C) With similar concerns and sufficient doubt arisingoverseas, the European Medicines Agency calledfor a new trial to investigate whether DrotAAwould reduce mortality in patients with septicshock PROWESS-SHOCK—a randomized, double-blind,placebo-controlled, multicenter trial of 1,697patients The researchers found no significant difference inefficacy between patients who received DrotAAand those who did not receive treatment. At 28days, 26.4% of patients in the treatment arm and24.2% of patients in the placebo arm had died.